疫苗是不指望喽 等我们死后吧
A vaccine designed to protect against genital herpes is Simplirix, in Phase III testing by GlaxoSmithKline. This consists of the gD2 subunit of herpes virus together with SBAS4, an adjuvant containing Corixa's MPL adjuvant to elicit T-cell responses. Drawbacks are that efficacy appears to be limited primarily to women who are seronegative for both HSVs 1 and 2.
----最后一句: 缺点是功效看起来基本只限于对HSV1和HSV2血清反应呈阴性的女性
--Laurie Barclay, M.D., August 2005